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ORIGINAL ARTICLE
Effects of Dexamethasone on Satellite Cells
and Tissue Engineered Skeletal Muscle Units
Brian C. Syverud, MS,1 Keith W. VanDusen, MS,2 and Lisa M. Larkin, PhD1,2
Tissue engineered skeletal muscle has potential for application as a graft source for repairing soft tissue injuries,
a model for testing pharmaceuticals, and a biomechanical actuator system for soft robots. However, engineered
muscle to date has not produced forces comparable to native muscle, limiting its potential for repair and for use
as an in vitro model for pharmaceutical testing. In this study, we examined the trophic effects of dexamethasone
(DEX), a glucocorticoid that stimulates myoblast differentiation and fusion into myotubes, on our tissue
engineered three-dimensional skeletal muscle units (SMUs). Using our established SMU fabrication protocol,
muscle isolates were cultured with three experimental DEX concentrations (5, 10, and 25 nM) and compared to
untreated controls. Following seeding onto a laminin-coated Sylgard substrate, the administration of DEX was
initiated on day 0 or day 6 in growth medium or on day 9 after the switch to differentiation medium and was
sustained until the completion of SMU fabrication. During this process, total cell proliferation was measured
with a BrdU assay, and myogenesis and structural advancement of muscle cells were observed through im-
munostaining for MyoD, myogenin, desmin, and a-actinin. After SMU formation, isometric tetanic force
production was measured to quantify function. The histological and functional assessment of the SMU showed
that the administration of 10 nM DEX beginning on either day 0 or day 6 yielded optimal SMUs. These
optimized SMUs exhibited formation of advanced sarcomeric structure and significant increases in myotube
diameter and myotube fusion index, compared with untreated controls. Additionally, the optimized SMUs
matured functionally, as indicated by a fivefold rise in force production. In conclusion, we have demonstrated
that the addition of DEX to our process of engineering skeletal muscle tissue improves myogenesis, advances
muscle structure, and increases force production in the resulting SMUs.
Introduction
Potential applications for engineered skeletal muscleinclude implantation as a graft material for repair of
traumatic damage,1,2 recapitulation of native development,
regeneration for detailed physiological study or pharma-
ceutical testing,3 and use as biomechanical actuators.4,5 In
each case, recreating the complex function and structure of
skeletal muscle in vivo is a challenging, but essential, con-
sideration. Engineered tissues to date, however, have been
characterized by a neonatal phenotype in terms of force
production and structural maturity.6,7 Following sufficient
recovery time, engineered skeletal muscles implanted into
an in vivo regenerative environment have advanced toward
the adult phenotype,8,9 and several studies have attempted to
utilize key chemical and mechanical stimuli to improve the
maturity of these engineered muscles in vitro.10,11
Tissue engineers have used the influence of such growth
factors on myogenesis to direct techniques for engineering
skeletal muscle. Current tissue engineering techniques utilize
scaffold materials, ranging from acellularized tissues12,13 to
collagen and fibrin hydrogels,3,6,14 or opt for a scaffold-free
approach7,9,15 to support development of extracellular matrix
(ECM) for subsequent muscle tissue. The ultimate success of
these approaches depends on the in vitro culture of isolated
primary muscle precursor cells. A common technique in
cultivation of these myogenic cells begins with an initial
proliferation phase, allowing cells to expand sufficiently,
followed by induction of differentiation and fusion into
myotubes.16 Use of media with high serum content is gen-
erally accepted to promote the initial proliferation phase
while delaying the onset of differentiation, potentially due to
the presence of a variety of growth factors.17 Drastic reduc-
tion in media serum content subsequently triggers satellite
cell differentiation, possibly due to the removal of essential
mitogenic components. Because of variations in the activity
and concentration of growth factors between lots of com-
mercially available serum, and the consequent variability in
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satellite cell induction and proliferation, an optimum serum
formulation and the identity of these mitogenic components
has yet to be fully defined.18 By understanding the essential
growth factors and supplementing media with the appropriate
doses, tissue engineers can maximize the myogenic potential
of satellite cells when engineering skeletal muscle.
The synthetic glucocorticoid dexamethasone (DEX) has
previously been studied due to its profound effects on muscle
in vivo and on satellite cell cultures in vitro, but its application
in skeletal muscle tissue engineering has yet to be evaluated.
In a clinical setting, DEX is typically used for its anti-
inflammatory or immunosuppressant activity to treat several
rheumatologic and skin diseases, because it is 25 times more
potent than endogenous cortisol.19 In skeletal muscle spe-
cifically, exogenously delivered DEX has a variety of effects
depending on the timing and dosage of the administration.
DEX induces atrophy in adult human skeletal muscle when
supplied orally in 4mg doses, *10 times greater than en-
dogenous cortisol levels.20,21 This atrophic effect has been
linked to upregulation of the myostatin promoter and inhi-
bition of IGF-1 expression.20,22 In contrast, the administra-
tion of 5–25 nM DEX has improved myogenesis in vitro by
enhancing differentiation and myotube fusion of myogenic
murine cells, potentially through its induction of dysferlin, a
calcium-binding transmembrane protein thought to play a key
role in both myogenesis and membrane repair.23 Similar
studies have demonstrated that DEX can inhibit protein
synthesis and myoblast proliferation in vitro,24 however, re-
inforcing the need for careful timing of addition to culture.
Recent research from our lab has focused on optimizing
and testing skeletal muscle units (SMUs), cylindrical tissue
constructs featuring muscle fabricated from monolayers of
primary fibroblasts and contractile myotubes.9 The articles
referenced above regarding DEX activity in vitro describe
its effects on the immortal C2C12 mouse myoblast cell line
in two-dimensional culture, rather than the primary cell
population and functional three-dimensional (3D) constructs
used in our SMU experiments. We hypothesized that ex-
posing the heterogeneous pool of satellite cells and fibro-
blasts used for SMU fabrication to different doses of DEX at
several time points may yield an optimal combination for
improving myogenesis and ultimately maximizing in vitro
development of our engineered skeletal muscle. Thus, the
purpose of this study was to examine the potential of the
steroid DEX as a growth factor for skeletal muscle tissue
engineering.
Materials and Methods
Animal care
Tissue engineering studies were conducted using soleus
muscles and bone marrow from 145 to 155 g female Fischer
344 rats, obtained from Charles River Laboratories, Inc.
(Wilmington, MA) and Harlan Laboratories (Haslett, MI).
All animals were acclimated to colony conditions for 1 week
before any procedure. Animals were fed Purina Rodent Chow
5001 and water ad libitum. All surgical procedures were
performed in an aseptic environment, with animals in a deep
plane of anesthesia induced by intraperitoneal injections of
sodium pentobarbital (65mg/kg). Supplemental doses of
pentobarbital were administered as required to maintain an
adequate depth of anesthesia. All animal care and animal
surgery procedures were in accordance with The Guide for
Care and Use of Laboratory Animals,25 and the protocol was
approved by the University Committee for the Use and Care
of Animals.
SMU formation and DEX addition
SMUs were fabricated in individual coated 60mm poly-
styrene plates (BD Falcon, Franklin Lakes, NJ), and immu-
nocytochemistry (ICC) was performed on 35mm plates as
described previously.7,9,26 Briefly, a substrate of Sylgard
(type 184 silicon elastomer; Dow Chemical Corp., Midland,
MI) was initially cured onto each plate, followed by coating
with laminin (Natural Mouse Laminin; Cat. No. 23017-015;
Gibco BRL, Carlsbad, CA) at 1mg/cm2. The cell isolation
mixture was plated in muscle growth medium (MGM) at a
density of 600,000 cells per 60mmplate and 150,000 cells per
35mm plate. MGM contained 30mL F-12 Kaighn’s modifi-
cation nutrient mixture (Cat. No. 21127-022; Gibco BRL),
12.5mLDulbecco’s modified Eagle’s medium (DMEM; Cat.
No. 11995-065; Gibco BRL), 7.5mL fetal bovine serum
(FBS; Cat. No. 10437-028; Gibco BRL), 2.4 ng/mL basic fi-
broblast growth factor (Cat. No. 100-18B; Peprotech, Rocky
Hill, NJ), and 0.5mL antibiotic-antimycotic (ABAM; Cat.
No. 15240-062; Gibco BRL).
After the initial plating, cells were left undisturbed for
4 days and subsequently fed MGM every 2 days until be-
coming fully confluent with elongating myotubes forming a
network across the base of the plate. At this point, 5mm tissue-
engineered bone-tendon anchors were pinned onto the cell
monolayers 2.5 cm apart, and the media was switched to
muscle differentiation medium (MDM). MDMwas composed
of 35mL M199 (Cat. No. 11150-059; Gibco BRL), 11.5mL
DMEM, 3mLFBS, 50mL insulin-transferrin selenium-X (Cat.
No. I1884; Sigma-Aldrich, St. Louis, MO), 0.5mL ABAM,
and 36.2mL 50mM ascorbic acid 2-phosphate. After approx-
imately a week on MDM, resupplied every other day, the
monolayers delaminated from the plates, rolling into cylin-
drical muscle constructs, held at length by the engineered bone
anchors. During this SMU formation process, described in
Figure 1, DEX was added to the media beginning at three
different time points: initial plating (day 0), 6 days after initial
plating (day 6), and 2 days after the switch to MDM (day 9).
These three time points were chosen to evaluate the efficacy of
DEX in controlling isolated cell proliferation, differentiation,
and maturation of the delaminating monolayer and subsequent
3D SMU, respectively. After the first addition, supplemental
doses of DEX were added with each media change. Three
experimental doses were supplied (5, 10, and 25nM), with
untreated plates as controls.
SMU contractile measurements
Contractile properties of SMUs (n = 6) from each exper-
imental group were measured following roll-up into cy-
lindrical form. The protocol for measuring contractility of
engineered muscle constructs has been described previous-
ly.27,28 Briefly, the pin on one end of the SMU was raised
from the Sylgard and attached to a force transducer. Plati-
num wire electrodes were placed along either side of the
SMU for field stimulation. The temperature of the construct
was maintained at 37C, using a heated aluminum platform.
Passive force was measured as the average baseline force
DEXAMETHASONE ENGINEERED SKELETAL MUSCLE 481
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/11
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
produced before the onset of stimulation. Twitch contrac-
tions were elicited using a single 2.5ms pulse at 10, 30, 60,
and 90 mA, whereas tetanic force was determined using a
1 s train of 2.5ms pulses at 90 mA and 10, 20, 40, 60, and
80Hz. Data files for each peak twitch force and peak tetanic
force trace were recorded and subsequently analyzed using
LabVIEW 2012.
Immunocytochemical analysis
During SMU fabrication, a subset of the plates from each
experimental group was fixed in 20C methanol for 10min
and set aside for ICC. The plates were submerged for 15min
in 0.1% Triton X-100 (Cat. No. T8787; Sigma) in DPBS
(PBST) and blocked with PBST containing 3% bovine serum
albumin (PBST-S; Cat. No. A2153; Sigma) at room tem-
perature. The sections were then incubated overnight at 4C
with the primary antibodies diluted in PBST-S. Immuno-
fluorescent staining with specific antibodies was performed to
detect the presence of BrdU (biotin conjugated sheep poly-
clonal antibody; Cat. No. ab2284; Abcam, Cambridge, MA),
MyoD (mouse monoclonal antibody 1:100 dilution; Cat. No.
554130; BD Biosciences, San Jose, CA), fibroblast-specific
protein 1 (FSP1; rabbit polyclonal antibody 1:100 dilution;
Cat. No. ab27957; Abcam), myogenin (rabbit polyclonal
antibody 1:50 dilution; Cat. No. sc-576; Santa Cruz Bio-
technology, Dallas, TX), desmin (mouse monoclonal anti-
body 1:20 dilution; Cat. No. D3; Developmental Studies
Hybridoma Bank, Iowa City, IA), and a-actinin (mouse
monoclonal antibody 1:200 dilution; Cat. No. A7752; Sigma).
Plates stained with antibodies for BrdU had previously been
incubated for 24 h with a BrdU labeling reagent (Cat. No. 00-
0103; Life Technologies, Carlsbad, California) in the culture
media. Following three washes in PBST, samples were in-
cubated in 1:500 dilutions of Alexa Fluor anti-mouse, anti-
rabbit, or streptavidin secondary antibodies (Life Technolo-
gies) for 3 h at room temperature. Following three washes in
PBST, samples were preserved in Prolong Gold with DAPI
(Cat. No. P36935; Life Technologies) and cover slipped. The
samples were examined and photographed with a Leica In-
verted microscope, and images were analyzed using the Im-
age J software package.
For ICC analysis, plates (n = 5) from each experimental
group were fixed and stained (on day 4 for BrdU, MyoD, and
FSP1; day 7 formyogenin; and day 11 for desmin). From each
plate, 10 areas were randomly selected and imaged, and the
number of positively stained nuclei in each image was
counted. To calculate myotube fusion index from the desmin
images, the number of nuclei associated with a desmin-
positive myotube was divided by the total number of nuclei.
Myotube size and density analysis
On day 14 after initial plating of satellite cells, light
micrographs of the developing monolayers in each experi-
mental group were captured and analyzed. Specifically, five
areas from each 60mm plate (n= 8) were randomly selected
and imaged. Every myotube from these images was then
measured in ImageJ to determine its size and the overall
density of the myotube network.
FIG. 1. Experimental timeline. Addition of DEX was initiated at three time points: on day 0 to study effects on
proliferation, on day 6 to study effects on late proliferation and differentiation, and on day 9 to study effects on structural
maturation. During this SMU fabrication process, subsets of the developing plates were analyzed for expression of BrdU,
MyoD, FSP1, myogenin, and a-actinin as listed above. Additionally, myotube fusion and myotube size and density were
measured in the developing muscle monolayers. Finally, the 3D SMUs were assessed for force production in response to
electrical stimulation and for structural development with TEM. 3D, three-dimensional; DEX, dexamethasone; FSP1,
fibroblast-specific protein 1; MDM, muscle differentiation medium; MGM, muscle growth medium; SMU, skeletal muscle
unit; TEM, transmission electron microscope.
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Transmission electron microscopy analysis
Following measures of mechanical function, SMUs were
fixed overnight at room temperature in 0.1M phosphate
buffer (Cat. No. S369-500; Fisher Scientific, Pittsburgh, PA)
containing 2.5% glutaraldehyde (Cat. No. 16210; Electron
Microscopy Sciences, Hatfield, PA), postfixed at 4C for 1 h
in 0.1M phosphate buffer containing 1% osmium tetroxide
(Cat. No. 19150; Electron Microscopy Sciences), and po-
lymerized in Embed 812 resin (Cat. No. 14900; Electron
Microscopy Sciences) at 60C for 24 h. Ultra-thin 70 nm
sections were then cut and stained with uranyl acetate (Cat.
No. 22400; Electron Microscopy Sciences) and lead citrate
(Cat. Nos. 17900 and 21140; Electron Microscopy Sciences)
and imaged using a JEOL JEM-1400Plus transmission
electron microscope (TEM).
Statistical analysis
Values are presented as mean – SE. Measurements of
significant differences between means were performed using
R software. Means were compared using either one-way or
two-way ANOVA tests with Tukey post hoc comparisons.
Differences were considered significant at p < 0.05.
Results
Effects of DEX on proliferation of satellite cells
To assess the influence of DEX on the induction and pro-
liferation of isolatedmyogenic satellite cells, DEXwas added
at the time of plating (day 0). ICC analysis of cells expressing
BrdU, a synthetic nucleoside analog of thymine, was used on
day 4 to identify proliferating cells,29 and expression of
MyoD and FSP1 was examined simultaneously to identify
myogenic cells and matrix-secreting fibroblasts, respectively
(Fig. 2). From the analysis of BrdU and MyoD co-staining, a
dose-dependent response to DEX treatment was evident, with
the density of proliferating myogenic nuclei increasing with
increasing DEX concentration. Following addition of 10 and
25 nMDEX, a statistically significant increase in MyoD+ cell
proliferation relative to No DEX controls was observed
( p= 0.012 and 0.003, respectively). Addition of 5 nM DEX
exhibited no difference from controls and resulted in signif-
icantly fewer proliferating MyoD+ cells than the 10 and
25 nM DEX doses ( p = 0.037 and 0.009, respectively). Si-
milarly, ICC analysis for both BrdU and FSP1 showed that
the administration of DEX on day 0 led to a decrease in the
number of proliferating FSP1+ cells. This decrease in FSP1+
cells was significant following 10 and 25 nM DEX addition,
relative to untreated controls ( p = 0.002 and 0.004, respec-
tively). Administration of 5 nM DEX indicated no difference
in FSP1+ cells fromNoDEX controls. In comparison to the 10
and 25 nM concentrations, however, 5 nM DEX yielded sig-
nificantly decreased proliferation of FSP1+ cells ( p = 0.004
and 0.005, respectively). Thus, the results for MyoD and
FSP1 expression in proliferating cells demonstrate that the
influence of 10 and 25 nM DEX on early growth of hetero-
geneous muscle isolates was twofold: improved proliferation
of cells in the myogenic lineage and decreased proliferation
of non-myogenic fibroblasts.
DEX induction of muscle cell differentiation
and myotube fusion
ICC analysis of myogenin expression was used as an in-
dicator of myoblast differentiation into myotubes on day 7 of
the experiment.30 A dose-dependent increase in myogenin-
positive cell density was observed in response to DEX
treatment, independent of the timing of its addition (Fig. 3A).
Groups receiving 5 nM DEX showed no difference from
No DEX controls, whereas 10 nM addition significantly
FIG. 2. Myogenic and fibroblast cell proliferation following DEX addition. (A) With DEX addition on the day of initial
seeding (D0), the percentage of proliferating cells expressing MyoD followed an increasing trend with increasing DEX
concentration, as indicated by BrdU and MyoD co-staining on day 4. A statistically significant increase in proliferation
( p = 0.012 for 10 nM, p= 0.003 for 25 nM) was observed when comparing the higher concentrations of DEX (10 and 25 nM)
to untreated controls (No DEX). (B) ICC analysis for BrdU and FSP1 on day 4 showed a decrease in the percentage of
proliferating cells expressing FSP following DEX addition. In response to administration of 10 and 25 nM DEX, the number
of proliferating cells expressing FSP1 significantly decreased relative to No DEX controls ( p = 0.002 and 0.004, respec-
tively). Error bars indicate mean – standard error. *Indicates statistical difference from control, #from 5 nM DEX. ICC,
immunocytochemistry.
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increased the number cells expressing myogenin ( p = 0.001),
and 25 nM DEX led to even greater increases ( p < 0.001).
Ultimately, treatment with 25 nM DEX beginning on day 6
yielded the highest density of myogenin+ cells, *2.8 times
greater than untreated controls.
Myotube fusion index was measured to assess the ability of
myoblasts to terminally differentiate and form a network of
myotubes in the presence of DEX. Expression of desmin, a
protein specific to muscle cells and a key subunit in inter-
mediate filaments,17,31 identified fused myotubes, and sub-
sequent analysis of the percentage of nuclei associated with a
myotube yielded a myotube fusion index value. Two-way
ANOVA indicated that both the dose and timing of DEX
addition significantly affected myotube fusion (Fig. 3B).
Compared with untreated controls, all three experimen-
tal concentrations significantly increased myotube fusion
( p = 0.002 for 5 nM, p > 0.001 for 10 and 25 nM). The effect
of time indicates that the early addition of DEX at cell seeding
(day 0) or toward the end of the proliferative stage (day 6)
significantly increased myotube fusion ( p = 0.015 and 0.008,
respectively), whereas plates treated with DEX during the
differentiation stage (day 9) exhibited no difference from
controls. Although no difference in myotube fusion was ob-
served between the 5, 10, and 25 nM concentrations when
averaged across the three timing groups, focus on the day 6
time point alone revealed a dose-dependent trend, with fusion
index increasing with each DEX concentration. This trend
included a statistically significant difference between the day
6 DEX concentrations of 5 and 25 nM ( p = 0.007). Across
all experimental groups, addition of 25 nM DEX on day 6
yielded the highest myotube fusion index at 69%, a 250%
increase over the No DEX controls. The combined results for
myogenin expression and myotube fusion demonstrate that
DEX addition increased myogenic differentiation and myo-
tube fusion, with the addition of the highest experimental
dose, 25 nM, on day 6 producing the greatest increases.
Further analysis of myotube size and number was per-
formed on day 14, immediately before monolayer delami-
nation. The dose and timing of DEX addition were observed
to have significant effects on myotube diameter (Fig. 4B). In
response to the experimental DEX concentrations, a sig-
nificant dose-dependent increase in myotube diameter was
observed, resulting in myotubes 1.23, 1.34, and 1.41 times
larger than No DEX controls following addition of 5, 10,
and 25 nM DEX, respectively ( p = 0.001 for 5 nM, p< 0.001
for 10 and 25 nM). Additionally, in plates receiving DEX at
the two early time points, day 0 and day 6, myotube di-
ameters increased significantly relative to untreated controls
( p < 0.001 for both days). Plates subsequently treated with
DEX on day 9 showed no difference in myotube diameter
from controls. Day 6 addition of 10 and 25 nM DEX pro-
duced the largest myotubes, with average diameters of 14.8
and 16.1 mm, respectively. Myotube diameters for both do-
ses were significantly greater than control myotubes, which
had an average diameter of 9.8 mm ( p < 0.001 for both do-
ses). The effects of the timing of DEX addition on the
overall density of the myotube network were also evident.
Administration of DEX on day 6 improved myotube density
significantly ( p = 0.008), while addition of DEX on day 0
and day 9 exhibited no significant differences from un-
treated controls. Similarly, no significant differences were
observed when examining the influence of the three DEX
FIG. 3. DEX effects on myogenic differentiation. (A) ICC analysis for myogenin on day 7 indicated terminal differen-
tiation of myoblasts into myotubes. Following two-way ANOVA, a dose-dependent increase in myogenin-positive cell
density was observed in response to DEX ( p < 0.001), independent of the timing of addition. (B) Myotube fusion index,
calculated from desmin and DAPI staining on day 11, quantified the number of nuclei associated with a myotube as a
percentage of total nuclei. Two-way ANOVA indicated a significant effect of both DEX dose and timing ( p < 0.001 for
both). When averaged across the three timing groups, all three DEX concentrations yielded significantly increased myotube
fusion relative to No DEX controls ( p= 0.002 for 5 nM, p > 0.001 for 10 and 25 nM). Similarly, fusion index increased
significantly with DEX addition on day 0 and day 6 ( p = 0.015 and 0.008, respectively). Error bars indicate mean – standard
error. *Indicates statistical difference from No DEX controls, #from 5 nM in the same DEX timing group, Afrom 10 nM in
the same timing group, {from 25 nM in the same timing group, afrom day 0 at the same DEX dose, bfrom day 6 at the same
DEX dose, and cfrom day 9 at the same DEX dose.
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doses on myotube density. Together, the myotube size and
density data indicate that the addition of DEX on day 6 leads
to a more robust network of larger myotubes, which may be
preferable for engineering skeletal muscle.
Structural and functional maturation of 3D SMUs
with DEX addition
The influence of DEX on the overall structure and function
of engineered SMUs was also observed during delamination
and in the final 3D form. Immunocytochemical analysis of a-
actinin (Fig. 5A, B) demonstrated improved maturation of
myotubes in the delaminating monolayer following addition
of all three DEX concentrations. Plates receiving DEX on day
0 and day 6 exhibited advanced sarcomeric structure within
highly aligned myofibrils in the confluent monolayers. This
development of sarcomeric structure was not observed in
control muscle cultures or plates receiving DEX during the
differentiation stage on day 9. Similarly, administration of
DEX led to improved structural maturation in the fully
formed 3D SMUs. Electron micrographs of a SMU receiving
10 nM DEX on day 6 suggested an increase on the density of
aligned collagen fibers at the junctions of each myofiber,
indicating a more developed ECM than the No DEX SMU
(Fig. 5C, D). Furthermore, following 10 nM DEX adminis-
tration on day 6, the resulting SMU demonstrated develop-
ment of aligned myofilaments and maturing Z-lines, similar
to the organization of parallel sarcomeres in adult skeletal
muscle (Fig. 5E, F). Aligned myofilaments were evident in
untreated control SMUs, but few developing sarcomeric
structures were observed.
This improved structural maturation translated to increased
function, as assessed by contractile force production in the 3D
SMUs. The maximum isometric tetanic forces produced by
engineered SMUs are displayed in Figure 6A, and two-way
ANOVA indicated both DEX timing and dose significantly
affected SMU function. When averaging the values across all
experimental concentrations to study timing effects, admin-
istration of DEX on day 0 and day 6 both led to a significant,
twofold increase in force production ( p = 0.016 for day 0,
p = 0.018 for day 6). Addition of DEX on day 9 led to a 20%
decrease in force production compared to No DEX controls.
Surprisingly, however, when examining the effects of DEX
dosage, only addition of 10 nM DEX produced a significant
improvement in function, represented by a fivefold increase
in isometric force production relative to No DEX controls
FIG. 4. DEX effects on myotube growth. Monolayers were observed just before delamination on day 14. Representative
images are shown above for (A) No DEX, (B) day 6 (5 nM), (C) day 6 (10 nM), and (D) day 6 (25 nM). Images from the day
6 timing group were chosen because this time point demonstrated the significant effects of DEX addition detailed below. All
images were analyzed for (E) myotube diameter and (F) myotube density. The effects of DEX dose and timing on myotube
size were both evident from two-way ANOVA ( p < 0.001 for both). Post hoc analysis demonstrated significant increases in
myotube diameter in response to all three DEX concentrations ( p = 0.001 for 5 nM, p< 0.001 for 10 and 25 nM). Similarly,
day 0 and day 6 DEX addition led to significantly increased myotube diameters relative to untreated controls ( p< 0.001 for
both days). When examining myotube density, the timing of DEX addition had a significant effect ( p = 0.004). Specifically,
the number of myotubes increased significantly with DEX addition on day 6 in comparison to No DEX controls ( p= 0.008),
but day 0 and day 9 addition resulted in no significant difference. Scale bars = 100mm. Error bars indicate mean – standard
error. *Indicates statistical difference from No DEX controls, afrom day 0 at the same DEX dose, bfrom day 6 at the same
dose, and cfrom day 9 at the same dose.
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( p = 0.004). SMUs receiving 5 nM DEX showed no increase
relative to control SMUs, whereas addition of 25 nM DEX
significantly decreased force production ( p= 0.024). Overall,
optimal force production was observed in SMUs receiving
10 nM DEX on day 0 and day 6, with average isometric te-
tanic forces of 256.5 and 253.6 mN, respectively.
Additionally, administration of DEX may have affected the
development and maintenance of passive tension in the ma-
turing muscle monolayers, and eventually in the SMUs fabri-
cated from the monolayers. This passive tension effect was
quantitatively observed in the timing of delamination of the
developing monolayers. Rather than rolling up on day 14 as is
typical in our SMU fabrication protocol, plates treated with
DEX remained inmonolayer form*20% longer, regardless of
the dosage administered. Plates receiving DEX rolled up, on
average, on day 17, andmanualmanipulationwas occasionally
necessary to assist this process. Following delamination, pas-
sive tension development in the newly formed SMUs was
measured during assessment of contractile force production
24 h post roll-up. Two-way ANOVA indicated a significant
effect of both DEX timing and dose on passive tension
(Fig. 6B). Further analysis showed that addition of DEX ad-
dition significantly decreased passive tension in fabricated
SMUs ( p< 0.001 for days0 and6,p= 0.006 for day9,p< 0.001
for 5 nM, p= 0.003 for 10 nM, and p= 0.002 for 25 nM), re-
gardless of the timing or dose of DEX administration.
FIG. 5. SMU structural maturation with DEX addition. Representative images of muscle monolayers (A) without DEX
and (B) following DEX addition (day 0, 10 nM). These images show a-actinin in muscle monolayers 10 days post-seeding.
Formation of advanced sarcomeric structure and aligned myofibrils was evident in plates receiving DEX on either day 0 or
day 6 in all three experimental concentrations. Transmission electron micrographs of longitudinal sections of SMUs
following formation of a 3D construct, (C, E) without DEX administration and (D, F) following day 6 addition of 10 nM
DEX, corroborate the positive effects of DEX on structural maturation during SMU fabrication. Both No DEX and day 6,
10 nM DEX images show developing extracellular matrix at myofiber junctions, but greatly increased density and alignment
of collagen fibers is evident following DEX addition. Similarly, both SMUs contain myofibers with highly aligned myo-
filaments, indicated by asterisks in (C, D). However, the formation of organized Z-lines indicative of developing sarcomeric
structure was observed to a much greater extent in SMUs receiving DEX administration, evident in (E, F). Scale bars in (A,
B) 50mm, (C, D) 4mm, (E, F) 600 nm.
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Discussion
The overall effects of DEX during the SMU fabrication
process can be divided into distinct proliferation, differ-
entiation, and maturation phases. The addition of DEX
before myocyte differentiation led to improved myogenic
proliferation and suppression of non-myogenic prolifera-
tion, indicated by increased MyoD+ cell density and de-
creased FSP1+ cell density. In addition, administration of
10 and 25 nM DEX at the beginning of proliferation (day
0) or 1 day before the transition from proliferation to dif-
ferentiation (day 6) yielded increased myoblast fusion,
resulting in a dense network of larger myotubes in the
subsequent differentiation phase. Similarly, addition of
DEX during the proliferative stage on either day 0 or day 6
resulted in the greatest structural maturation of the dela-
minating monolayers and the resulting fully formed 3D
SMUs, characterized by the presence of advanced sarco-
meric structure within highly aligned myofibrils. Ulti-
mately, administration of 10 nM DEX during proliferation
on either day 0 or day 6 yielded optimal force production
in fabricated SMUs.
FIG. 6. SMU functional maturation with DEX addition. (A)Analysis of the functional measures of isometric tetanic force in
3D SMUs indicated a significant effect of both DEX dose and timing ( p < 0.001 for dose, p= 0.004 for timing). One can
conclude that the addition of 10 nM DEX is optimal for SMU fabrication, since this concentration produced a significant,
fivefold increase in force production relative to untreated controls ( p = 0.004). Additionally, day 0 and day 6 administration of
DEX both led to a significant, twofold increase in force production ( p= 0.016 for day 0, p = 0.018 for day 6), whereas day 9
DEX addition actually yielded a 20% decrease in force production compared to No DEX controls. (B) Examination of passive
force generation in fabricated SMUs also showed a significant effect of DEX timing and dose ( p = 0.004 for timing, p < 0.001
for dose). Further analysis indicated that DEX treatment led to significant decreases compared with No DEX controls
regardless of DEX timing or concentration ( p < 0.001 for days 0 and 6, p = 0.006 for day 9, p < 0.001 for 5 nM, p= 0.003 for
10 nM, p= 0.002 for 25 nM). Error bars indicate mean – standard error. *Indicates statistical difference fromNoDEX controls,
#from 5 nM in the sameDEX timing group,Afrom 10 nM in the sameDEX timing group, {from 25 nM in the sameDEX timing
group, afrom day 0 at the same DEX dose, bfrom day 6 at the same dose, and cfrom day 9 at the same dose.
DEXAMETHASONE ENGINEERED SKELETAL MUSCLE 487
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/11
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
Although administration of 25 nM DEX improved myo-
genic proliferation and differentiation, force production in
these SMUs actually decreased compared with No DEX
controls. Several factors potentially explain the ultimate
decrease in the contractile function associated with addition
of 25 nM DEX. As described above, supplementation with
DEX led to decreased non-myogenic proliferation and in-
creased myogenesis, concomitant with decreased passive
tension. ECM is essential to SMU fabrication, both for
generation of the passive tension promoting delamination
and for structural support of the contractile components of
the SMU. Although TEM images indicated increased col-
lagen deposition and alignment following DEX treatment
(Fig. 5C, D), this increase in collagen content did not
translate to a stiffer ECM, as evidenced by the decrease in
passive tension values. It is possible that a more compliant
ECM was beneficial to myogenesis. Since plates receiving
25 nM DEX exhibited the largest myotubes in the highest
density, however, additional ECM would be required to
support these robust muscle networks, and it is possible that
the ECM present in the 25 nM plates was insufficient to
transmit force along the SMUs.
Another potential explanation was the formation of blebs
on the periphery of several myotubes accompanying myo-
blast fusion. This blebbing typically began shortly after the
switch from MGM to MDM on day 7 and became more
pronounced during differentiation. Upon gross examination,
these blebs were increasingly prevalent at the 25 nM DEX
dosage. Blebbing has been identified as a potential bio-
marker of cell injury that can occur in myotubes in response
to toxic agents or hypotonic osmotic shock.32 Based on the
current understanding of the action of DEX in vivo,20,22
namely acting as a potential agent for the induction of
skeletal muscle atrophy, it may be possible to draw a con-
nection between DEX addition and myotube membrane
damage and blebbing. Further analysis is necessary to de-
termine whether membrane blebbing, an inhibition of ECM
formation, or some additional unexpected cause, resulted in
the decrease in force production accompanying 25 nM DEX
addition.
In conclusion, this experiment demonstrates that addition
of DEX to isolated muscle satellite cells in culture can im-
prove functional and structural characteristics of our tissue
engineered skeletal muscle when administered at optimal
doses and timings. Addition of DEX before induction of
differentiation improved myogenic proliferation of muscle
satellite cells, which subsequently led to increased myo-
genic differentiation and myotube fusion. The benefits of the
administration of DEX during proliferation were further
evident during the SMU maturation phase, as characterized
by formation of advanced sarcomeric structure and in-
creased contractile function observed in the fully formed 3D
SMU. The most promising improvements in SMU function
were achieved with the addition of 10 nM DEX on either
day 0 or day 6. In addition to increased myogenic differ-
entiation and myotube fusion, SMUs exposed to this con-
centration exhibited advanced structural development of
sarcomeric structure and a fivefold increase in force pro-
duction. Thus, the utilization of DEX in our existing tissue
engineering model presents a blueprint for advancing tissue
engineering of skeletal muscle.
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